[Drugs used in cardiovascular diseases and cytokines].
Immunopharmacological studies show that medicines used in cardiovascular diseases (atherosclerosis, ischaemic heart disease, heart failure) can exert immunomodulatory effects on proinflammatory cytokines. In the paper the influence of statins, fibrates, angiotensin converting enzyme inhibitors (ACEI), beta-blockers, calcium channel blockers and phosphodiesterase inhibitors on the activity of cytokines was introduced.
Andrzejczak
Dariusz
D
Z Zakładu Farmakodynamiki Uniwersytetu Medycznego w Lodzi. dandrzejczak@pharm.am.lodz.pl
Górska
Dorota
D
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D050197:Atherosclerosis / Q000188:drug therapy / Q000276:immunology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000276:immunology*; D016207:Cytokines / Q000378:metabolism*; D006333:Heart Failure / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000378:metabolism; D017202:Myocardial Ischemia / Q000188:drug therapy / Q000276:immunology; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D016207:Cytokines; D007155:Immunologic Factors; D010726:Phosphodiesterase Inhibitors